Hypervision Surgical, a King’s College London spin-out pioneering the next generation of intraoperative imaging, is accelerating its mission to transform surgical decision-making. Following UKCA certification and FDA clearance of its first hyperspectral vision platform, and with multi-centre clinical evaluations underway in UK hospitals, the company is now scaling its on-chip hyperspectral imaging (HSI) and real-time artificial intelligence (AI) analytics to power global adoption of intelligent surgical vision.
Overcoming the barriers to hyperspectral imaging in clinical practice
Hyperspectral Imaging (HSI) has long shown promise in providing critical tissue-level insights – such as oxygenation, perfusion, and tissue differentiation – but until now, its clinical adoption has been limited. Previous systems have struggled with integration due to hardware complexity, slow processing speeds, and poor compatibility with surgical workflows, limiting their use to research settings or post-operative analysis.
Hypervision has overcome these challenges with the world’s first regulatory-cleared intraoperative imaging platform, combining on-chip HSI with real-time AI analytics operating at over 60 frames per second. This breakthrough enables ultra-compact, high-frame-rate spectral sensing systems that integrate seamlessly into existing surgical vision platforms and workflows.
By embedding HSI natively into the operating room, Hypervision is unlocking high-fidelity spectral tissue imaging at a scale and speed previously unattainable – revealing anatomical, physiological, and pathological detail beyond the limits of human vision, and making advanced tissue-level analytics accessible in routine clinical practice.